HomeGreater Than Icon
Vaishali Pharma LtdGreater Than Icon
Vaishali Pharma Ltd Financials
Company Logo

Vaishali Pharma Ltd Financial Statement

Vaishali Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue18.50
Operating Expense15.74
Net Profit1.70
Net Profit Margin9.19
Earning Per Share1.48
EBIDTA2.77
Effective Tax Rate20.58

Vaishali Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual86.28
Operating Expenses Annual85.14
Operating Profit Annual3.17
Interest Annual1.74
Depreciation0.38
Net Profit Annual0.72
Tax Annual0.21

Vaishali Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.98
Cash Flow from Operations0.81
Cash Flow from Investing1.20
Cash Flow from Financing-1.42
Cash Flow at the End1.58

Vaishali Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)4.29
PBIT Margin (%)3.70
PBT Margin (%)2.07
Net PROFIT Margin (%)0.83
Return On Networth / Equity (%)1.73
Return On Networth /Employed (%)5.71
Return On Assets (%)1.29
Total Debt / Equity (X)0.34
Asset Turnover Ratio (%)1.54

Vaishali Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual2.26
Total Current Assets Annual74.52
Non Current Assets Annual5.44
Total Shareholders Funds Annual42.84
Total Assets Annual79.96

Vaishali Pharma Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Sep 19, 2024, Vaishali Pharma Ltd has a market capitalization of 150.12 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Vaishali Pharma Ltd is debt-free with a debt-to-equity ratio of 0.31.
In FY 2023 , Vaishali Pharma Ltd recorded a total revenue of approximately 86.28 Cr marking a significant milestone in the company's financial performance.
Vaishali Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.1% annually, respectively..
Vaishali Pharma Ltd's current PE ratio is 208.50.
Vaishali Pharma Ltd's ROCE averaged 13.9% from the FY ending March 2022 to 2024, with a median of 17.4%. It peaked at 19.6% in March 2023, reflecting strong capital efficiency over the period..
Vaishali Pharma Ltd's latest EBIT is Rs. 2.67 Cr, surpassing the average EBIT of Rs. 7.24 Cr over the 5 years..